Pharmaceutical Medicine, Biotechnology and European Lawby Richard Goldberg
Pub. Date: 03/28/2006
Publisher: Cambridge University Press
European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are grouped under four themes: free movement of goods and persons,
European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are grouped under four themes: free movement of goods and persons, competition and intellectual property; European drug regulation; biotechnology; and product liability and transnational health care litigation. This important study offers a valuable resource for the pharmaceutical and biotechnology industries, as well as legal academics and practitioners.
- Cambridge University Press
- Publication date:
- Edition description:
- New Edition
- Product dimensions:
- 5.98(w) x 9.02(h) x 0.75(d)
Table of Contents
Notes on the contributors; Preface; Introduction Richard Goldberg and Julian Lonbay; Part I. Free Movement of Goods and Persons, Competition and Intellectual Property: 1. The free movement of goods I: pharmaceuticals, patents and parallel trade Professor W. R. Cornish; 2. The free movement of goods II: pharmaceuticals, trade marks and parallel imports Belinda Isaac; 3. The free movement of health care professionals in the European Community Julian Lonbay; 4. EC competition law, drugs and intellectual property: recent developments Professor Leigh Hancher; Part II. European Drug Regulation: 5. Data protection and abridged applications for marketing authorisations in the pharmaceutical industry Ian Dodds-Smith; 6. The role of the European Medicines Evaluation Agency (EMEA) in the harmonisation of pharmaceutical regulation Antoine Cuvillier; Part III. Biotechnology: 7. The morality clauses of the Directive on the Legal Protection of Biotechnological Inventions: conflict, compromise, and the patent community Deryck Beyleveld, Professor Roger Brownsword and Margaret Llewelyn; Part IV. Product Liability and Transnational Health Care Litigation: 8. The development risk defence and the European Court of Justice; increased injury costs and the Supplementary Protection Certificate Richard Goldberg; 9. Transnational health care litigation and the Private International Law (Miscellaneous Provisions) Act 1995, Part III Jonathan Harris; Index.
and post it to your social network
Most Helpful Customer Reviews
See all customer reviews >